glp-1 fda shortage BREAKING: THE WILL NOT TAKE ACTION AGAINST COMPOUNDERS AFTER OZEMPIC ENDS source: Bloomberg : r/tirzepatidecompound The FDA says the shortage

Focus: Long-term health, metabolic optimization, comfortable maintenance

Its 2025 revenue amounted to $46.7 billion

Patients were included if they had baseline bilateral pain radiographs demonstrating Kellgren and Lawrence grades of 1 to 3, as well as at least 2 years of follow-up before the initiation of GLP-1RA therapy for the sake of comparisons between groups

Rare but serious risks include pancreatitis

Am J Clin Nutr 1981

In head-to-head comparison during the STEP trials, semaglutide 2.4 mg weekly produced significantly greater weight reduction than liraglutide 3.0 mg daily, approximately 15% versus 7% of body weight over similar timeframes